Tatarinan N inhibits osteoclast differentiation through attenuating NF-κB, MAPKs and Ca²⁺-dependent signaling

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Osteoclasts are crucial for bone remodeling, but their overactivation contributes to osteoporosis.
• Targeting osteoclastogenesis is a promising therapeutic strategy for osteoporosis.
• Previous research identified Tatarinan O as an inhibitor of osteoclast formation.

Purpose of the Study:

• To investigate the effects of three asarone-containing lignin-like compounds (Tatarinan N, U, and V) on osteoclastogenesis.
• To elucidate the molecular mechanisms by which Tatarinan N inhibits osteoclast formation and function.

Main Methods:

• Assessment of osteoclast differentiation, bone resorption, and F-actin ring formation in response to RANKL stimulation.
• Quantitative analysis of osteoclastogenesis-associated gene expression (TRAP, cathepsin K, MMP-9).
• Investigation of signaling pathways, including NF-κB, MAPKs (ERK1/2, p38, JNK), calcineurin, Btk-PLCγ2, intracellular Ca2+, and transcription factors NFATc1 and c-Fos.

Main Results:

• Only Tatarinan N (TN) significantly suppressed RANKL-induced osteoclast differentiation, bone resorption, and F-actin ring formation.
• TN dose-dependently inhibited the expression of key osteoclastogenesis genes (TRAP, cathepsin K, MMP-9).
• TN downregulated NFATc1 and c-Fos by inhibiting NF-κB activation and MAPK phosphorylation (ERK1/2, p38), while also attenuating calcineurin expression via the Btk-PLCγ2 cascade and reducing intracellular Ca2+.

Conclusions:

• Tatarinan N exhibits potent anti-osteoclastogenic activity.
• TN's mechanism involves the modulation of multiple signaling pathways critical for osteoclast differentiation and activation.
• These findings suggest that Tatarinan N holds therapeutic potential for treating osteoporosis.